Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients : a prospective cohort study
© 2023. The Author(s)..
To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). Prospective observational study of RA, axial (AxSpA) and peripheral SpA (PerSpA) patients initiating etanercept during 2004-2020. Kaplan-Meier plots were used for drug retention comparisons and multivariable Cox regression models for predictors of discontinuation. Long-term disease activity trajectories were identified by latent class growth models using DAS28-ESR or ASDAS-CRP as outcome for RA and AxSpA respectively. We assessed 711 patients (450 RA, 178 AxSpA and 83 PerSpA) with a median (IQR) follow-up of 12 (5-32) months. At 5 years, 22%, 30% and 21% of RA, AxSpA and PerSpA patients, respectively, remained on therapy. Etanercept discontinuation was independent of the diagnosis and was predicted by gender and obesity in both RA and SpA groups. Four disease activity (DA) trajectories were identified from 6th month of treatment in both RA and AxSpA. RA patients in remission-low DA groups (33.7%) were younger, had shorter disease duration, fewer comorbidities and lower baseline disease activity compared to moderate (40.6%) & high DA (25.7%) groups. In AxSpA 74% were in inactive-low DA and they were more often males, non-obese and had lower number of comorbidities compared to higher ASDAS-CRP trajectories. In RA and AxSpA patients, disease activity trajectories revealed heterogeneity of TNFi treatment responses and prognosis. Male gender, lower baseline disease activity and fewer comorbidities, characterize a favourable outcome in terms of disease burden accrual and TNFi survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Rheumatology international - 44(2024), 2 vom: 25. Jan., Seite 249-261 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flouri, Irini [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2024 Date Revised 21.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00296-023-05455-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363087702 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363087702 | ||
| 003 | DE-627 | ||
| 005 | 20240121231848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-023-05455-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1266.xml |
| 035 | |a (DE-627)NLM363087702 | ||
| 035 | |a (NLM)37815625 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Flouri, Irini |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients |b a prospective cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2024 | ||
| 500 | |a Date Revised 21.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). Prospective observational study of RA, axial (AxSpA) and peripheral SpA (PerSpA) patients initiating etanercept during 2004-2020. Kaplan-Meier plots were used for drug retention comparisons and multivariable Cox regression models for predictors of discontinuation. Long-term disease activity trajectories were identified by latent class growth models using DAS28-ESR or ASDAS-CRP as outcome for RA and AxSpA respectively. We assessed 711 patients (450 RA, 178 AxSpA and 83 PerSpA) with a median (IQR) follow-up of 12 (5-32) months. At 5 years, 22%, 30% and 21% of RA, AxSpA and PerSpA patients, respectively, remained on therapy. Etanercept discontinuation was independent of the diagnosis and was predicted by gender and obesity in both RA and SpA groups. Four disease activity (DA) trajectories were identified from 6th month of treatment in both RA and AxSpA. RA patients in remission-low DA groups (33.7%) were younger, had shorter disease duration, fewer comorbidities and lower baseline disease activity compared to moderate (40.6%) & high DA (25.7%) groups. In AxSpA 74% were in inactive-low DA and they were more often males, non-obese and had lower number of comorbidities compared to higher ASDAS-CRP trajectories. In RA and AxSpA patients, disease activity trajectories revealed heterogeneity of TNFi treatment responses and prognosis. Male gender, lower baseline disease activity and fewer comorbidities, characterize a favourable outcome in terms of disease burden accrual and TNFi survival | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Axial spondyloarthritis | |
| 650 | 4 | |a Disease activity trajectories | |
| 650 | 4 | |a Drug survival | |
| 650 | 4 | |a Etanercept | |
| 650 | 4 | |a Psoriatic arthritis | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Tumor necrosis factor inhibitor | |
| 650 | 7 | |a Etanercept |2 NLM | |
| 650 | 7 | |a OP401G7OJC |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Goutakoli, Panagiota |e verfasserin |4 aut | |
| 700 | 1 | |a Repa, Argyro |e verfasserin |4 aut | |
| 700 | 1 | |a Bertsias, Antonios |e verfasserin |4 aut | |
| 700 | 1 | |a Avgoustidis, Nestor |e verfasserin |4 aut | |
| 700 | 1 | |a Eskitzis, Anastasios |e verfasserin |4 aut | |
| 700 | 1 | |a Pitsigavdaki, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Kalogiannaki, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Terizaki, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Bertsias, George |e verfasserin |4 aut | |
| 700 | 1 | |a Sidiropoulos, Prodromos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d 1985 |g 44(2024), 2 vom: 25. Jan., Seite 249-261 |w (DE-627)NLM012644315 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:2 |g day:25 |g month:01 |g pages:249-261 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00296-023-05455-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 2 |b 25 |c 01 |h 249-261 | ||